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http://www.biomedcentral.com/2050-6511/15/31RESEARCH ARTICLE Open AccessMedication errors related to transdermal opioid
patches: lessons from a regional incident
reporting system
Henrik Lövborg1,2*, Mikael Holmlund1 and Staffan Hägg1Abstract
Objective: A few cases of adverse reactions linked to erroneous use of transdermal opioid patches have been
reported in the literature. The aim of this study was to describe and characterize medication errors (MEs) associated
with use of transdermal fentanyl and buprenorphine.
Methods: All events concerning transdermal opioid patches reported between 2004 and 2011 to a regional
incident reporting system and assessed as MEs were scrutinized and characterized. MEs were defined as “a failure in
the treatment process that leads to, or has the potential to lead to, harm to the patient”.
Results: In the study 151 MEs were identified. The three most common error types were wrong administration
time 67 (44%), wrong dose 34 (23%), and omission of dose 20 (13%). Of all MEs, 118 (78%) occurred in the
administration stage of the medication process. Harm was reported in 26 (17%) of the included cases, of which 2
(1%) were regarded as serious harm (nausea/vomiting and respiratory depression). Pain was the most common
adverse reaction reported.
Conclusions: Of the reported MEs related to transdermal fentanyl and buprenorphine, most occurred during
administration. Improved routines to ascertain correct and timely administration and educational interventions to
reduce MEs for these drugs are warranted.
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The usage of transdermal patches which allows continu-
ous and prolonged delivery of medications is increasing.
Less frequent dosing, lower peak plasma drug concen-
tration compared with other types of administration
forms and avoidance of first-passage metabolism are
some reported benefits suggesting that this administra-
tion form may have increased compliance, effectiveness
and safety compared to oral administration [1,2]. In
addition, patches offer the potential to deliver medica-
tions that would otherwise require injections. Moreover,
future advances in the technology will probably increase
the utilization of drug patches further.* Correspondence: Henrik.Lovborg@lio.se
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unless otherwise stated.Sporadic case reports indicate however specific prob-
lems related with this drug form, such as incorrect use of
multiple patches [3,4], ingestion of used or unused patches
[5] and skin reaction [6]. Since potent drugs linked to ser-
ious adverse reactions are administered through transder-
mal patches, medication errors may lead to serious
adverse health consequences. The American Food and
Drug Administration (FDA) states that opioids poses the
highest risk of harm and death, among approved transder-
mal patches, because of their risk to cause respiratory de-
pression [7] and has, along with other organizations,
issued warnings regarding unsafe use of these patches
[8,9]. There are also previous reports of serious and fatal
cases due to erroneous administration of multiple patches
of rivastigmine, an anticholinergic drug used to treat de-
mentia [4,10]. Prevalence and characteristics of medica-
tions errors related to transdermal opioid patches has notl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tific literature and such information is needed to develop
effective preventive measures. This study was therefore
undertaken to describe and characterize medication errors
regarding transdermal opioid patches, containing fentanyl




Reports on medication errors were identified in a web-
based incident reporting system for the healthcare
organization within the County Council of Östergötland,
Southeastern Sweden. Permission to access the data was
obtained from the patient safety department of the
Couty Council. Ethical review was not required for this
study, based on national legislation [11]. The database
did not contain information that was directly or indir-
ectly identifying individual subjects. The catchment area
in this study comprised 431 075 persons (2011). All are
encouraged to report all types of incidents and risks. In-
cident and risk were defined by the county council as
“an unexpected event or observation that leads to or has
the potential to lead to harm to a patient, relative or
family member, employee, equipment, or organization”.
In this study all events concerning transdermal opioid
patches reported between 2004 and 2011 were scruti-
nized. The data included free text description of the inci-
dent, reporting clinic, and date of the incident.
Cases
For incident reports to be included in this study they
had to be classified as MEs according to the definition “a
failure in the treatment process that leads to or has the
potential to lead to harm to patients” [12], and concern
transdermal opioid patches with fentanyl or buprenor-
phine as active ingredients (e.g. fentanyl in Durogesic
and Matrifen or buprenorphine in Norspan). “Pain relief
patch” is a commonly used term for these patches
among healthcare employees and MEs described with
this term have accordingly been included. To reliably
identify reports when searching the database, the key
terms used included the words patch, fentanyl, buprenor-
phine, transdermal, Norspan, Durogesic, Matrifen and a
number of misspellings of these terms. Patches with e.g.
lidocaine for local anesthetic use were excluded.
Classification
During ME classification substance, drug brand name,
harm, reactions, and error type have been determined.
Serious harm was classified in accordance with the
WHO definition of a serious adverse event or reaction, i.e.
a reaction that results in death, requires inpatient
hospitalization or prolongation if existing hospitalization,results in persistent disability/incapacity, or is life threat-
ening [13]. The MedDRA (Medical Dictionary for Regula-
tory Activities) terminology was used describe the type of
adverse reactions reported [14]. In some reports more
than one incident was described. In this case incidents
considered to causally relate to the first one in the medica-
tion process was not included. Also sequentially repeated
incidents of the same type in a single report were classi-
fied as a single incident. 60 proposed error types, as previ-
ously described [15] were used to categorize the MEs
(Table 1), based on the free text description of the case.
Reports were anonymized and were not traceable back to
medical records. Therefore no thorough root cause ana-
lysis was possible to perform. Due to lack of information
in some incident reports the error type “unclassifiable”
was added, and to further analyze our results sub-error
types were created for “wrong time” and “wrong dose”.
The authors collectively developed the inclusion and exclu-
sion criteria and data extraction. Inclusion of and extraction
of data was performed by MH and HL by consensus.
Results
During the study period a total of 102 270 incident re-
ports were submitted. Selection of opioid patch related
MEs are shown in Figure 1. Of all incident reports 13,3%
(n = 13 617) concerned medications. Of these, 279 con-
tained at least one of the key terms and were reviewed.
Of the reviewed incident reports 149 were selected for
this study in accordance with the inclusion criteria. In
two incident reports more than one ME was found
which resulted in two additional MEs and a total of 151
MEs were included in the analysis. Of the MEs, 66%
(n = 100) concerned fentanyl, 28% (n = 42) unknown sub-
stance, and 6% (n = 9) buprenorphine. Of the included
MEs 48% (n = 73) were reported during 2010 and 2011.
In total, 11 different types of MEs were identified.
Some error types may however be found in several
stages of the medication process while others are stage
specific (Table 1). Administration errors were most com-
monly reported, and the most frequently occurring error
in this category was administration at the wrong time
(n = 67). In the prescribing stage wrong transcription er-
rors were most common (n = 9), and in the dispensing
stage wrong dose (n = 4), shown in Table 2.
MEs in the prescribing stage were often due to incor-
rect use of electronic systems for prescribing or elec-
tronic medical records. In the dispensing stage slips and
lapses occurred as causes, and in the administration step
lack of compliance with routines, e.g. scheduling visits
to outpatients to change patch, was a common cause.
The two most frequent error types reported, wrong time
and wrong dose, were further analyzed by the addition
of subtypes. Wrong time MEs were divided into late
(92%, n = 62), early (3% n = 2) and unknown (5%, n = 3).
Table 1 Categories of error types used in this study [15]
Prescribing Dispensing Administration and monitoring
Decision making Communication




- Calculation error - Decimal place error - Incompatibility errors - Extra dose
- Interaction drug and disease - Ambiguous drug name - Contamination - Lack of control of patient identity
- Expired drug
- Interaction between
drug and laboratory test
- Ambiguous drug prescription - Omission of dose - Omission of dose
- Drug to drug interaction - P.r.n. prescription without
a maximum limit
- Omission of documentation
of drug dispensing
- Lack of documentation of
the drug administration
- Extra drug - P.r.n. prescription without
a minimum dose interval
- Omission of control of
the drug prescription
- Lack of control of agreement
between administered drug
and prescribed drug- Omission of a
drug prescription
- Wrong concentration - Omission of indication for
treatment including p.r.n.
prescriptions
- Substitution error - Unordered drug
- Wrong drug form - Unordered drug - Wrong dose
- Wrong dose - Unordered electrolyte - Wrong patient
- Wrong dosing interval - Wrong concentration - Wrong dosing interval
- Wrong drug
- Illegible handwriting - Wrong drug form - Wrong rate
- Wrong route
of administration





- Extra dose - Wrong technique
- Wrong strength/unit - Wrong strength per unit - Wrong time




- Wrong dilution fluid - Omission of documentation
of side-effects of the drug
treatment
- Wrong transcription
The error types are listed from left to right in the order of the medication process.
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scheduling of visits and assigning personnel to the task
of changing patches were the most common cause of
late administration.
Of the 34 MEs with wrong dose, 13 were cases of too
high dose, 10 were cases of too low dose, and 4 with un-
specified wrong dose. Of the cases with too high dose, 7
were cases where the old patch were not removed before
a new patch was applied.
Harm was reported for 17% (n = 26) of the MEs as shown
in Table 3. In two cases there were reports of serious harm.
In the first case a patient who ingested a fentanyl patch is
described. This patient experienced a respiratory depression
and during intubation for respiratory care the patch was
discovered in the pharynx. The second case concerns a pa-
tient who received a higher dose than prescribed. At admit-
tance to hospital health care personnel found two sets of
patches of the prescribed dose on the patient, who was ex-
periencing nausea, vomiting, and pain. The observed ad-
verse reactions (in some cases more than one reaction per
ME) were pain (n = 16), withdrawal syndrome (n = 4),fatigue (n = 3), anxiety (n = 2), discomfort (n = 1), dizziness
(n = 1), respiratory depression (n = 1), nausea/vomiting
(n = 1), tremor (n = 1) and confusional state (n = 1).
Discussion
This is, to our knowledge, the first systematic study
assessing and categorizing medication errors concerning
transdermal opioid patches. A considerable proportion,
54%, of the MEs assessed in this study constitutes of
wrong time - late and omission of doses. The difference
between these two error types was the time of discovery;
incidents discovered before the next administration were
categorized as wrong time – late and incidents discov-
ered at the next scheduled administration or later were
categorized as omission of dose. These errors often ap-
peared to be caused by unsatisfactory planning and inad-
equate patch changing routines. As for all error types,
we were unable to perform a full root cause analysis to
fully explain what occurred prior to the errors of late ad-
ministration. It is also important to note that incidents
and errors are often consequences of failures in the
Total number of 
incident reports














Exclusion of reports of 
non-medication 
incidents
Exclusion of reports 
not containing the 
word patch
Exclusion of non-
MEs or other 
transdermal drugs
Figure 1 Scheme of case selection.
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information that was not available in this dataset on a
case by case basis.
Wrong dose constituted 23% of the reported MEs, a
diverse error type that was further divided into several
subtypes. Analyzing wrong dose – high as well as wrong
dose – low, we found that difficulties in handling doses
consisting of more than one patch, often with different
strengths, sometimes caused problems. Studies have
shown that the amount of drug present in used fentanyl
patches may be high, in some cases up to 60% of the ini-
tial amount [17,18]. As well as potential risk of causing
an overdose this could enhance other risks associated
with fentanyl use, such as the risk for ADRs. Due to
these facts we have considered forgetting to remove old
patches when applying a new ones as potentially harmful
and this is an important dosage form specific ME. Con-
stituting 21% of the reports of wrong doses, the risks
with forgetting old patches on patients may not beconsidered negligible. Educating healthcare personnel in
transdermal opioid pain management and the import-
ance of carefully checking patient for old patches before
applying new ones would likely reduce the risk of
overdosing.
Of all prescribing MEs, 74% were categorized as wrong
transcription or omission of a drug prescription. Mutual
for these two error types is that there seemed to be is-
sues concerning electronic prescribing systems and
knowledge about how to use it properly. There were also
cases where a prescription was noted in the medical rec-
ord but not transcribed into a separate system for order-
ing multi-dose packaging. Knowledge about routines
related to documenting drug related information in the
journal appeared to be another issue. At the same time
it is important to note that these systems are likely to re-
duce mediation errors relating to prescriptions [19,20].
In our study we also found one case of ingestion of a
fentanyl patch, which ended up causing the patient
Table 3 Patient harm by error type
Error type No harm Harm
Nonserious Serious
Omission of dose: n = 20 12 8 0
Wrong time: n = 67 59 8 0
Wrong dose: n = 34 27 6 1
Wrong transcription: n = 9 8 1 0
Wrong technique: n = 3 2 1 0
Wrong route of administration: n = 1 0 0 1
Remaining error types 17 0 0
SUM: n = 151 125 24 2
Table 2 Error types found in the different stages of the medication process
Error type Prescribing Dispensing Administration Unknown† Total (%)
Wrong time 0 1 66 67(44)
Wrong dose 4 4 25 1 34(23)
Omission of dose 0 2 18 20(13)
Wrong transcription 9 0 0 9(6)
Unclassifiable* 0 0 0 6 6(4)
Omission of a drug prescription 5 0 0 5(3)
Lack of documentation of the drug administration 0 0 2 2(1)
Wrong dosing interval 0 0 2 2(1)
Wrong technique 0 0 3 3(2)
Ambiguous drug prescription 1 0 0 1(1)
Lack of control of agreement between administered drug and prescribed drug 0 0 1 1(1)
Wrong route of administration 0 0 1 1(1)
SUM (%) 19(112) 7(5) 8(78) 7(5) 151 (100)
*MEs with no suitable error type †Data didn’t provide enough information to determine in what stage in the medication process the ME occurred.
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whole fentanyl patch ingestion reports hospital admit-
tance in about 78% of the cases with serious adverse
reactions like coma, respiratory depression and tachycar-
dia [5]. Patient education regarding the serious risks that
this type of misuse can cause could possibly increase the
safety in using these types of drugs, with the exception
of intentional misuse. The second case of serious harm
in our study was categorized as wrong dose – high; a pa-
tient who was treated with a relatively high dose, 250 μg,
was discovered to have two sets of patches of the pre-
scribed dose on his body at the same time. This most
likely contributed to his symptoms that caused admis-
sion. Both accidental and voluntary misuse of fentanyl
patches causing fatal and nonfatal intoxications are de-
scribed in the literature [17,21].
The third most commonly reported error type, omis-
sion of dose, had the highest proportion of harm (40%).
Most common reaction in this category was, as ex-
pected, that the patients suffered from pain break-
through and withdrawal symptoms. Omission of dose, as
well as late doses, was often related to inadequate rou-
tines for scheduling and performing change of patch.
Interestingly several studies states that using transder-
mal patches may increase compliance [22,23], but an
American study reviewing 644 medication errors with
opioids found a higher rate of omission errors with fen-
tanyl patches then with other opioids in different dosage
forms, 36% and 12% respectively [1,23,24]. This is in line
with our data where reports on omission of doses were
relatively common.
The three most commonly reported error types i.e.
wrong time, wrong dose, and omission of dose, consti-
tute 80% of all MEs included in this study. Of these 90%
occurred in the administration phase of the medicationprocess. We suspected that this uneven distribution of
MEs in the medication process partly could be explained
by which profession that had predominantly reported
the cases included in this study. However this data was
not accessible for the years 2004 and 2005, but for the
remaining years nurses were submitting the vast major-
ity of the reports (not shown). This may have influenced
in what phase of the medication process and what type
of errors that were reported. We also suspect that we
have an underestimation of MEs in the dispensing stage
since neither hospital nor community pharmacies were
reporting MEs to the database used in this study.
There are some limitations of this study that needs to
be taken into consideration when interpreting the re-
sults. Even though reporting incidents to the database
used in this study is mandatory for the employees in the
county council, underreporting is substantial. It has been
estimated that at most 10% of all incidents in our region
are reported (personal communication patient safety of-
ficer). It is also likely that certain categories of healthcare
personnel are more prone to report particular error
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common these errors are in the clinical setting. How-
ever, the lack of published data on specific problems re-
lating to transdermally delivered drugs warrants this
kind of study to capture signals and patterns on MEs
with these drugs. In the analysis of MEs we did not have
access to medical records therefore some clinical infor-
mation about the incident, the measures taken and the
outcome for the patient was not available. We were not
able to check medical record or interview personnel and
patients. Doing so would have yielded a deeper under-
standing of the causes of the errors performed. However,
that was neither possible using this data source, nor the
scope of this study. Another limitation was the fact that
the time of discovery could not always be assessed. Inci-
dents where omission of dose could not be accurately
determined were categorized as wrong time-late. As
most of the patients had healthcare personnel adminis-
tering the fentanyl or buprenorphine patches, we only
came across very few cases where the patients were self-
administrating, a setting with a potentially different pat-
tern of MEs. Furthermore, it is essential to know that
ME is a term that is quite imprecisely used in the litera-
ture and there are numerous definitions [15,25]. This
makes studies in this field difficult to compare. Inclusion
of cases considered a ME according to our definition, is
to some extent subjective. To reduce the risk of mis-
classification, only cases where the assessors reached a
consensus, were included.
Conclusions
Using an incident reporting system we were able to de-
scribe and characterize medication errors related to
transdermal fentanyl and buprenorphine. The vast ma-
jority of the reported errors occurred during administra-
tion. Improved routines to ascertain correct and timely
administration of these drugs and educational interven-
tions focusing on this stage of the medication process
are suggested.
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